FDA approves Pfizer COVID-19 vaccine
A Food and Drug Administration advisory panel approved of broad distribution of the Pfizer COVID-19 vaccine, the Wall Street Journal reports.
Loading the front page…
A Food and Drug Administration advisory panel approved of broad distribution of the Pfizer COVID-19 vaccine, the Wall Street Journal reports.
A Food and Drug Administration advisory panel approved of the broad distribution of the Pfizer COVID-19 vaccine, the Wall Street Journal reports.
After a day-long hearing on the efficacy of the vaccine produced by Pfizer Inc. and its partner BioNTech SE, the FDA's Vaccines and Related Biological Products Advisory Committee voted 17-to-4, with one abstention, in favor of the vaccine's approval, according to the WSJ.
The FDA panel reportedly decided that the benefits of the vaccine outweighed the associated risks for people older than 16 years of age.
The disease is now "essentially out of control," Kathrin Jansen, Pfizer’s head of vaccine research and development, told the panel.
"Vaccine introduction is an urgent need," she continued.
There are expected to be enough doses of the vaccine to immunize 20 million high risk individuals by the end of the year, according to Health and Human Services Secretary Alex Azar.
The FDA will reportedly allow emergency authorizations for use starting Friday.
Loading this lets YouTube set cookies and collect data.
View on YouTubeLibby’s Desk
Commentary and must-reads from Libby’s desk, straight to your inbox.
TPM Newsletter
The Post Millennial’s top stories, delivered to your inbox.
